SCHEMBL7879648

SCHEMBL7879648

CCN(CC)Cc1ccc(COc2ccc(C(F)(F)F)c3cc(C(=O)N(C)C(=N)N)[nH]c23)cc1

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.35
HRH3 Q9Y5N1 1/20 0.35
S1PR1 P21453 3/20 0.35
RXRA P19793 3/20 0.34
RXRB P28702 3/20 0.34
RXRG P48443 3/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
RHEB Q15382 1/20 0.32
CCR5 P51681 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.32
PKM P14618 1/20 0.32
ALOX15 P16050 1/20 0.32
ROCK2 O75116 1/20 0.32
BCHE P06276 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7877796 0.92 GYS1 (0.38) L3MBTL1MRGPRX4
SCHEMBL7877966 0.92 S1PR1 (0.36) S1PR1RXRARXRBRXRGMEN1
SCHEMBL7873759 0.90 SCN9A (0.37) ACHEMEN1KMT2A
SCHEMBL7884316 0.89 S1PR1 (0.37) S1PR1RXRARXRBRXRGRHEB
SCHEMBL7880877 0.88 RHEB (0.40) ACHEHRH3L3MBTL1MEN1KMT2A
SCHEMBL7880033 0.88 FFAR1 (0.35) ACHES1PR1MEN1KMT2APKM
Hydrochloric Acid SCHEMBL7873300 0.87 S1PR1 (0.40) S1PR1RXRARXRBRXRGMRGPRX4
SCHEMBL7877440 0.85 S1PR1 (0.34) S1PR1RXRARXRBRXRGRHEB
SCHEMBL7881492 0.84 MRGPRX4 (0.37) S1PR1L3MBTL1MRGPRX4ROCK2
SCHEMBL7881823 0.84 SCN9A (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed